Edition:
United Kingdom

People: Biohaven Pharmaceutical Holding Company Ltd (BHVN.N)

BHVN.N on New York Stock Exchange

61.83USD
24 May 2019
Change (% chg)

$1.12 (+1.84%)
Prev Close
$60.71
Open
$61.14
Day's High
$62.07
Day's Low
$60.76
Volume
54,592
Avg. Vol
132,118
52-wk High
$65.55
52-wk Low
$29.17

Tilton, John 

Mr. John Tilton is a Chief Commercial Officer, Rare and Orphan Diseases of Biohaven Pharmaceutical Holding Company Limited. Mr. Tilton has served as our chief commercial officer, rare and orphan diseases since April 2019 and, prior to that, as our chief commercial officer since April 2016. Prior to this, from November 2006 to March 2016, he served in increasingly senior marketing and business roles with Alexion Pharmaceuticals, Inc., including serving as its executive director, global sales and marketing operations from January 2011 to March 2016. Prior to his time at Alexion Pharmaceuticals, Mr. Tilton served as a director, division operations at Pfizer from August 2005 to November 2006, as a regional sales manager for Agouron Pharmaceuticals from November 1999 to August 2005 and as division manager at Sanofi from 1993 to 1999. Mr. Tilton received his BSBA in finance from the University of South Carolina—Columbia.

Basic Compensation

Total Annual Compensation, USD 1,506,820
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 18,849
Fiscal Year Total, USD 1,525,670

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Declan Doogan

706,360

Vlad Coric

7,854,000

James Engelhart

3,217,070

Kimberly Gentile

2,784,540

Charles Conway

2,792,860

Robert Berman

521,060
As Of  31 Dec 2018